Abstract Glioblastoma, the most lethal brain tumor, remains incurable despite aggressive chemotherapy and surgical interventions. New chemotherapeutics for glioblastoma have been explored in preclinical models and some agents have reached the clinical setting. However, success rates are not significant. Previous investigations involving diallyl trisulfide (DATS), a garlic compound, indicated significant anticancer effects in glioblastoma in vitro. DATS has also been shown to inhibit histone deacetylase activity and impede glioblastoma tumor progression. We hypothesized that DATS would block ectopic U87MG tumor by multiple pro-apoptotic pathways via inhibiting histone deacetylase (HDAC). To prove this, we developed ectopic U87MG tumors in SCID mice and treated them daily with intraperitoneal injections of DATS for 7 days. Results indicated that DATS (10 lg/kg-10 mg/kg) dose-dependently reduced tumor mass and number of mitotic cells within tumors. Histological and biochemical assays demonstrated that DATS reduced mitosis in tumors, decreased HDAC activity, increased acetylation of H3 and H4, inhibited cell cycle progression, decreased protumor markers (e.g., survivin, Bcl-2, c-Myc, mTOR, EGFR, VEGF), promoted apoptotic factors (e.g., bax, mcalpian, active caspase-3), and induced DNA fragmentation. Our data also demonstrated an increase in p21Waf1 expression, which correlated with increased p53 expression and MDM2 degradation following DATS treatment. Finally, histological assessment and enzyme assays showed that even the highest dose of DATS did not negatively impact hepatic function. Collectively, our results clearly demonstrated that DATS could be an effective therapeutic agent in preventing tumor progression and inducing apoptosis in human glioblastoma in vivo, without impairing hepatic function.
Introduction
Glioblastoma is the most aggressive and malignant of all astrocytic tumors [1] . The current standard of care for glioblastoma often involves a multi-modal approach combining surgery, radiation, and/or chemotherapy [2] . Unfortunately, a cure for this deadly disease remains elusive. Therefore, developing an effective treatment strategy for glioblastoma is extremely important.
Garlic, a member of the allium family, contains an interesting and complex range of water-soluble and fatsoluble organosulfur compounds, some of which have been implicated as cancer chemopreventive agents [1] . Recently, allyl derivatives from garlic were among the first compounds described to impact histone acetylation status by increased acetylation of histones (H3 and H4) in human cancer cells [4] [5] [6] , implicating histone deacetylases (HDACs) as possible targets. However, the specific role of HDAC inhibition and histone acetylation in DNA damage signaling has not yet been elucidated in these studies. Others and we have previously demonstrated that diallyl trisulfide (DATS) inhibits in vitro growth of multiple cancer cell lines, including glioblastoma [2] [3] [4] . Similar findings in neuroblastoma cell lines strengthen this argument [5] . Our group previously demonstrated that DATS increased calpain and bax while reduced Bcl-2 expression to promote apoptotic death [2] . Though DATS treatment correlates with an increase in reactive oxygen species production, the fact that it does not seem to affect nondividing cells suggests that other pathways are more directly linked to DATS mediated anti-cancer activities [4] . DATS also inhibits HDAC [6, 7] , blocks G 2 /M phase of cell cycle, activates the Cdk1-Cdk2-Cdc25c pathway, and inhibits DNA damage response proteins [4, 8] . Recent reports also suggest that by suppressing oncogenic protein expression [2, 9] via HDAC inhibition [6, 7] , DATS may restore p53 function by raising p53 and p21waf1 levels and thus trigger cellular apoptosis in aberrantly dividing cells as seen in cancer. At the same time, in vivo studies of ectopically grown prostate tumors revealed that DATS significantly reduced tumor size without significantly altering liver enzyme levels or altering liver histological profiles [10] . It has been demonstrated that high doses of DATS (up to 62 mg/kg body weight) are tolerable in animal models [11] . In fact, 7-day oral treatments with 30 mg/ kg DATS do not show hepatotoxicity due to lack of elevated alkaline phosphatase (ALP) levels [12] .
Based on other studies and our previous in vitro findings [2] , we hypothesized that daily DATS treatment in ectopically grown U87MG tumors would cause decreases in tumor mass, mitotic index, and oncoprotein expression with concurrent increases in pro-apoptotic factors. Indeed, DATS reduced tumor mass and mitotic index by preventing cell cycle progression and oncoprotein expression while promoting apoptotic signaling and acetylation of histones (H3 and H4).
Methods
U87MG cell culture and ectopic glioblastoma xenografts U87MG cell line was obtained from American Type Culture Collection (ATCC, Manassas, VA) and grown to about 80 % confluency in 1xRPMI 1640 (Cellgro, Manassas, VA) with 10 % fetal bovine serum (BioAbChem, Ladson, SC) and 1 % penicillin/streptomycin (Cellgro) at 37°C with 5 % CO 2 . Cells were collected for xenotransplantation. Animal experiments were performed in compliance with Institutional Animal Care and Use Committee guidelines and the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD). We employed NOD CB17-prkdcSCID/J mice (Jackson Laboratory, Bar Harbor, ME). Approximately 1 9 10 6 U87MG cells suspended in 125 ll of 40 % media to 60 % Matrigel (BD Bioscience, Sparks, MD) were implanted subcutaneously over the right rear flank of anesthetized animals. Ectopic tumors were grown for 3 weeks before beginning daily treatment with DATS (LKT Laboratories, St. Paul, MN) for 7 days. DATS was suspended in sterile saline and delivered at a specific dose (10, 100 lg/kg, or 10 mg/kg). Tumors were removed and weighed before being quick frozen in Tissue Mounting Medium (TMM). Livers were also collected and stored similarly.
Hematoxylin & Eosin (H&E) staining of tumor and liver tissues Fresh frozen (-70°C) tumors and livers were cut (8 lm) on a cryostat and stored at -80°C prior to staining (Reichert-Jung, Leica, Deerfield, IL). Tissue was stained with Harris hematoxylin and counterstained with eosin (Fisher Scientific, Kalamazoo, MI) to examine histopathological characteristics of ectopic tumor and liver tissues. At least three images per slice and three slices per sample were taken at 4009 magnification with an Olympus fluorescent microscope (Olympus, Center Valley, PA) and mitotic bodies were counted using ImageJ cell counter software.
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) and fluorescent staining TUNEL assay was performed according to instructions for the dead end fluorometric TUNEL (Promega, Madison, WI). Survivin or m-calpain immunofluorescent staining was performed using our standard protocol. We used primary rabbit monoclonal anti-human survivin (AbCam, Cambridge, MA), mouse monoclonal anti-glial fibrillary acidic protein (GFAP, Chemicon, Temecula CA) and rabbit polyclonal anti-m-calpain (Santa Cruz Biotechnology). Also, we mounted the slides with vectashield with DAPI nuclear stain. A minimum of three images (2009 magnification) were captured for each section using Zeiss fluorescent microscope (Carl Zeiss, Thornwood, NY).
Analysis of genomic DNA fragmentation
Internucleosomal fragmentation of genomic DNA in the tumors was analyzed by agarose gel electrophoresis, as reported previously [13] .
Histone extraction and HDAC activity assay Histones were extracted from 2 9 10 6 cells, as described previously [6, 7] . Effects of DATS on HDAC activity was assessed using the HDAC colorimetric assay kit (EMD Millipore, Billerica, MA).
Western blotting
Western blotting was performed following our standard procedures [2] . Membranes were incubated with enhanced chemiluminescent reagents (ECL or ECL Plus, Amersham Biosciences, Piscataway, NJ) and imaged on Alpha-Innotech using FluorChem FC2 Imaging System. We stained one set of gel with Coomassie Blue to ensure loading of equal amounts of nuclear proteins in all lanes. Monoclonal antibody against b-actin (Sigma, St. Louis, MO) was used to standardize cytosolic protein loading on SDS-PAGE gels. Primary IgG antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA) or Calbiochem (Gibbstown, NJ). Secondary antibodies were horseradish peroxidase-conjugated goat antimouse IgG, horseradish peroxidase-conjugated rabbit antigoat IgG, and hors eradish peroxidase-conjugated goat antirabbit IgG (ICN Biomedicals, Solon, OH).
ALP assay
Following DATS treatment, we examined a toxicology biomarker to determine any hepatotoxicity associated with drug administration [14] [15] [16] . Homogenates of the liver tissues were used for the assessment of ALP levels using commercially available colorimetric assay kit (Biotron Diagnostics, Hemet, CA). Also, histopathological examination of liver tissue was performed for hallmark characteristics of drug toxicity via H&E staining [17] .
Statistical analyses
Data were gathered and processed in Microsoft Excel 2007 to determine sample means. Cell counts were conducted using the NIH ImageJ cell counter module from at least three images per slice and 3 slices per sample (n C 3). All statistical analyses were performed using the SPSS PASW statistical package. Means of all data by group were compared by ANOVA with Bonferroni's post hoc test where **p B 0.01 and *p B 0.05 were considered significant.
Results

DATS reduced visible tumor size, tumor mass, and mitosis
Ectopic U87MG xenografts in SCID mice were treated with DATS for 7 days (Fig. 1) . DATS dose-dependently reduced the visible size of U87MG tumors (Fig. 1a) . Measurement of tumor mass revealed that significant reductions in tumor mass ranging from 20 to 90 % occurred due to DATS administration at 10 lg/kg-10 mg/ kg, respectively (Fig. 1b) . About 50 % reduction in tumor mass occurred after treatment with 100 lg/kg DATS. Tumor sections from all treatments were subjected to H&E staining for histological evaluations under light microscope (Fig. 1c) . Examination of tumor sections helped quantify the mitotically active cells (Fig. 1d) . Treatment with DATS reduced the number of mitotic nuclei throughout tumor by about 50 % with 10 lg/kg DATS (p = 0.09), 70 % with 100 lg/kg DATS (p = 0.013), and nearly 80 % with 10 mg/kg (p = 0.002) when compared with untreated controls (Fig. 1d) .
DATS treatment decreased HDAC activity in tumors
Earlier studies demonstrated inhibition of HDAC activity by organosulfur compounds. So, we used colorimetric assay to measure HDAC activity after treatment of U87MG tumors with DATS ( Fig. 2) . We found that DATS dramatically reduced HDAC activity in tumors (Fig. 2a) . Western blotting showed strong induction of acetylation of histones H3 and H4, which correlated with HDAC inhibition (Fig. 2b, c) . These findings provided the first evidence that DATS acted as a HDAC inhibitor in glioblastoma in an animal model.
DATS inhibited cell cycle progression and promoted p53-mediated tumor suppression pathway
Western blotting was used to determine the role of cell cycle proteins and the p53-mediated tumor suppression pathway in tumor reduction following DATS treatment in U87MG xenografts (Fig. 3) . We observed significant reduction in the G2/M checkpoint regulator Cdk1 and its activator Cdc25c following DATS treatments. Increase in Tyr15 phosphorylation of Cdk1 suggested that Wee1 activity could work in concert with decrease in Cdc25c to prevent the G2/M phase transition (Fig. 3a, b) . At the same time, a significant increase in p21Waf1 correlated with an increase in p53 expression and mouse double minute two homolog (MDM2) degradation following DATS treatment (Fig. 3c, d ), suggesting re-activation of the G1/S phase transitional checkpoint. U87MG cells are known to contain wild-type p53 but mutated PTEN. Levels of PTEN remained unchanged after DATS treatments (Fig. 3c) . These results provide strong evidence that DATS reduces tumor growth by inhibiting cell cycle progression and promoting the p53-mediated tumor suppression pathway.
DATS reduced survivin and other oncoprotein expression and increased cell death markers
Fluorescent staining and Western blotting showed decreases in oncoproteins leading to cell death in tumors after DATS treatments (Fig. 4) . DATS dose-dependently decreased antiapoptotic survivin expression and increased TUNEL (marker of apoptotic DNA fragmentation) positive cells in U87MG xenografts (Fig. 4a) . Expression of m-calpain, a protease for promoting apoptosis, was visibly increased in tumors following DATS treatments (Fig. 4a) . Co-staining of cells with TUNEL and GFAP (marker of astrocytoma) revealed that increasing apoptotic death occurred in tumor cells with increasing doses of DATS (Fig. 4a) . Western blotting showed that survivin and other oncoproteins (p-Akt, c-Myc, and mTOR) and angiogenesis markers (EGFR and VEGF) were also decreased after DATS treatments (Fig. 4b) . To confirm apoptosis in tumors, we examined changes in various apoptotic markers by Western blotting (Fig. 4c) . Decrease in antiapoptotic Bcl-2 protein and increases in pro-apoptotic proteins (bax, mcalpain, and active caspase-3), and ICAD degradation confirmed activation of apoptosis in tumors after DATS treatments (Fig. 4c) . Also, increase in DNA laddering due to internucleosomal DNA fragmentation, the hallmark of apoptosis, occurred in the tumors when treated with 100 lg/ kg and 10 mg/kg DATS (Fig. 4d) .
DATS treatment did not affect hepatic morphology and ALP level
Drug-induced hepatic injury is the most common reason for withdrawal of an approved drug. So, we checked hepatic morphology (H&E) and the hepatic enzyme ALP levels (colorimetric assay) after DATS treatments (Fig. 5 ).
H&E staining of liver sections from mice revealed no morphological changes due to the highest DATS dose (Fig. 5a ). Colorimetric assay showed no significant change in the liver ALP levels in response to treatment with 10 lg/ kg-10 mg/kg DATS (Fig. 5b) .
Discussion
The aim of this study was to examine whether the garlic compound DATS could effectively reduce ectopic glioblastoma tumor burden. Indeed, DATS dose-dependently decreased tumor mass with significant reductions seen in 100 lg/kg and 10 mg/kg DATS treated animals (Fig. 1) . DATS also dose-dependently decreased mitotic indexes in tumors (Fig. 1 ). To date, no studies have shown similar effects using DATS treatment in ectopic glioblastoma xenograft models. The present investigation provides plausible mechanistic insight into the efficacy of DATS by showing, for the first time, that DATS is an inhibitor of HDAC activity in the glioblastoma xenograft model. It is well established that DATS and organosulfur compounds can induce tumor cell death by upregulating apoptotic factors including caspase activation, bax and bad increases, and Bcl-2 decrease [2, 9, 18, 19] . One mechanism may involve production of ROS by organosulfur compounds [11] . Diallyl disulfide (DADS; which differs from DATS by one sulfur atom) caused dissociation of glutathione-Stransferase to c-Jun kinase complex (a key anti-ROS action), strongly implying that DADS caused ROS production [20] . DATS can be a far more potent for the induction of ROS mediated apoptosis in prostate cancer cells-a finding later confirmed in glioblastoma cell lines [2, 21] . However, DATS does not appear to harm mitotically inactive cells [4] . Upregulation of p53 by DATS is perhaps due to decrease in MDM2 expression, and also p53 itself induces ROS production in response to DNA damage [22] . We found that DATS reduced the cell cycle progression marker Cdk1 (Fig. 3) . This effect could be related to decrease in Cdc25c mediated Cdk1 activation or to Wee1 inactivation of Cdk1, as suggested by Tyr15 phosphorylation [23] . Regardless, DATS seems to block G1/S and G2/M transitional capabilities in glioblastoma xenografts.
Survivin expression represents one of the most important indicators of tumor growth. Previous ectopic glioblastoma models have shown a significant reduction in mitotic activity following survivin RNA knockdown [24] . Indeed, survivin expression was decreased in a DATS dose-dependent manner in this study (Fig. 3) . Moreover, EGFR and VEGF levels were reduced in glioblastoma xenografts due to DATS treatment. DATS also decreased Bcl-2 and elevated bax, mcalpain, and active caspase-3, suggesting that DATS caused tumor reduction via induction of apoptosis.
How pro-apoptotic cascades are activated following DATS treatment remains unknown. One study has suggested a role for garlic derivatives in directly manipulating cellular and organelle membrane potentials to cause tumor cell death [25] . Others have suggested an epigenetic mechanism whereby anti-apoptotic oncogenes are suppressed by DATS inhibition of HDACs [11] , which is also supported by our current findings (Fig. 2) . DATS also reduced C-Myc levels (Fig. 4) . DATS, in addition to HDAC inhibition, may further prevent transcription directly by decreasing c-Myc expression and indirectly through c-Myc mediated histone acetylation [26] . Interestingly, our findings also suggest that efficacy of DATS does not require PTEN (Fig. 3) , which is inactive in U87MG cells, to affect pro-survival and pro-mitotic cascades (Fig. 4) -a finding supported by other studies [3, 11, 27, 28] . Downstream of PTEN, p-Akt levels remained unchanged, but this was insufficient to prevent p53 increase and MDM2 degradation (Fig. 3) . A decrease in mTOR, which is upstream of survivin, may explain that DATS mediates decrease in survivin and GFAP expression (Fig. 4) . Cell death (DNA fragmentation) and decrease in the proliferation after DATS treatment by using Ki67 (proliferation marker) was also observed (data not shown). Histologically normal liver and unchanged ALP levels suggest that little or no toxicity occurs after weeklong treatment with 10 mg/kg DATS (Fig. 5) . These findings are in line with previous high-dose DATS efficacy reports [11, 12] . In this study, we have shown that DATS inhibits HDAC activity to promote apoptosis.
Taken together, the results demonstrated that DATS could be an effective therapy in preventing tumor progression and inducing apoptosis in human glioblastoma in vivo without hepatic toxicity. Although our results suggest potential mechanisms by which DATS promote death in tumors, more work is necessary to understand the efficacy of DATS and its pharmacokinetics in orthotopic glioblastoma xenograft models (using multiple glioblastoma cell lines). The success of these strategies in animal models will form the basis for translation of DATS therapy to glioblastoma in humans. 
